Table 1.7MM Prevalent Population of Idiopathic Pulmonary Fibrosis
Table 2.United States Prevalent Population of Idiopathic Pulmonary Fibrosis, by severity 2017-2030
Table 3.United State Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Table 4.United State Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Table 5.EU 5 Prevalent Population of Idiopathic Pulmonary Fibrosis, by severity 2017-2030
Table 6.EU 5 Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Table 7.EU 5 Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Table 8.UK Prevalent Population of Idiopathic Pulmonary Fibrosis, by severity 2017-2030
Table 9.UK Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Table 10.UK Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Table 11.France Prevalent Population of Idiopathic Pulmonary Fibrosis, by severity 2017-2030
Table 12.France Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Table 13.France Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Table 14.Germany Prevalent Population of Idiopathic Pulmonary Fibrosis, by severity 2017-2030
Table 15.Germany Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Table 16.Germany Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-20304
Table 17.Spain Prevalent Population of Idiopathic Pulmonary Fibrosis, by severity 2017-2030
Table 18.Spain Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Table 19.Spain Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Table 20.Italy Prevalent Population of Idiopathic Pulmonary Fibrosis, by severity 2017-2030
Table 21.Italy Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Table 22.Italy Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Table 23.Japan Prevalent Population of Idiopathic Pulmonary Fibrosis, by severity 2017-2030
Table 24.Japan Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Table 25.Japan Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Table 26.Comparison of Recommendations in the 2015 and 2011 Idiopathic Pulmonary Fibrosis Guidelines (New and Revised Recommendations)
Table 27.Comparison of Recommendations in the 2015 and 2011 Idiopathic Pulmonary Fibrosis Guidelines (Unchanged Recommendations)
Table 28.Total Market Size of Idiopathic Pulmonary Fibrosis in the 7MM
Table 29.Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in the US
Table 30.Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in the UK
Table 31.Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in France
Table 32.Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Germany
Table 33.Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Spain
Table 34.Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Italy
Table 35.Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Japan

Figure 1.Market Share (%) Distribution of Idiopathic Pulmonary Fibrosis in 2017
Figure 2.Market Share (%) Distribution of Idiopathic Pulmonary Fibrosis in 2030
Figure 3.Porters Five Forces Analysis
Figure 4.7MM Prevalent Population of Idiopathic Pulmonary Fibrosis, By Country, 2017-2030
Figure 5.United State Prevalent Population of Idiopathic Pulmonary Fibrosis, by severity, 2017-2030
Figure 6.United State Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Figure 7.United State Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Figure 8.EU 5 Prevalent Population of Idiopathic Pulmonary Fibrosis, by severity, 2017-2030
Figure 9.EU 5 Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Figure 10.UK Prevalent Population of Idiopathic Pulmonary Fibrosis, by severity, 2017-2030
Figure 11.UK Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Figure 12.UK Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Figure 13.France Prevalent Population of Idiopathic Pulmonary Fibrosis, by severity, 2017-2030
Figure 14.France Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Figure 15.France Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Figure 16.Germany Prevalent Population of Idiopathic Pulmonary Fibrosis, by severity, 2017-2030
Figure 17.Germany Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Figure 18.Germany Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Figure 19.Spain Prevalent Population of Idiopathic Pulmonary Fibrosis, by severity, 2017-2030
Figure 20.Spain Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Figure 21.Spain Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Figure 22.Italy Prevalent Population of Idiopathic Pulmonary Fibrosis, by severity, 2017-2030
Figure 23.Italy Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Figure 24.Italy Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Figure 25.Japan Prevalent Population of Idiopathic Pulmonary Fibrosis, by severity, 2017-2030
Figure 26.Japan Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Figure 27.Japan Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
Figure 28.Total Market Size of Idiopathic Pulmonary Fibrosis in the 7MM
Figure 29.Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in the 7MM
Figure 30.Market Size of Idiopathic Pulmonary Fibrosis in the US
Figure 31.Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in the US
Figure 32.EU5 Market Outlook
Figure 33.Market Size of Idiopathic Pulmonary Fibrosis in UK
Figure 34.Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in the UK
Figure 35.Market Size of Idiopathic Pulmonary Fibrosis in France
Figure 36.Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in France
Figure 37.Market Size of Idiopathic Pulmonary Fibrosis in Germany
Figure 38.Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Germany
Figure 39.Market Size of Idiopathic Pulmonary Fibrosis in Spain
Figure 40.Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Spain
Figure 41.Market Size of Idiopathic Pulmonary Fibrosis in Italy
Figure 42.Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Italy
Figure 43.Market Size of Idiopathic Pulmonary Fibrosis in Japan
Figure 44.Therapy Based Market Size of Idiopathic Pulmonary Fibrosis in Japan